Vitamin Shoppe, Inc (NYSE:VSI) had its target price trimmed by Barclays PLC from $6.00 to $3.00 in a research note issued to investors on Thursday morning. The firm currently has an equal weight rating on the specialty retailer’s stock.
VSI has been the topic of several other reports. Bank of America Corporation restated an underperform rating and set a $5.00 target price (down from $5.50) on shares of Vitamin Shoppe in a research report on Wednesday, August 23rd. Zacks Investment Research cut shares of Vitamin Shoppe from a hold rating to a sell rating in a research report on Tuesday, August 15th. ValuEngine downgraded shares of Vitamin Shoppe from a buy rating to a hold rating in a report on Friday, September 1st. Deutsche Bank AG reiterated a hold rating and set a $7.00 price target (down from $14.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Finally, Morgan Stanley reiterated an equal weight rating and set a $7.50 price target (down from $8.00) on shares of Vitamin Shoppe in a report on Monday, October 2nd. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Vitamin Shoppe currently has a consensus rating of Hold and a consensus price target of $5.00.
Shares of Vitamin Shoppe (NYSE VSI) remained flat at $$3.50 during midday trading on Thursday. 709,300 shares of the stock traded hands, compared to its average volume of 511,542. The company has a current ratio of 2.07, a quick ratio of 0.32 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $83.92, a PE ratio of 3.76 and a beta of 0.74. Vitamin Shoppe has a 1-year low of $2.95 and a 1-year high of $26.60.
Vitamin Shoppe (NYSE:VSI) last announced its earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.20). The business had revenue of $288.20 million for the quarter, compared to analysts’ expectations of $297.61 million. Vitamin Shoppe had a negative net margin of 20.27% and a positive return on equity of 6.17%. The firm’s quarterly revenue was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.50 earnings per share. equities research analysts predict that Vitamin Shoppe will post 0.53 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Barclays PLC Cuts Vitamin Shoppe, Inc (VSI) Price Target to $3.00” was published by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/barclays-plc-cuts-vitamin-shoppe-inc-vsi-price-target-to-3-00/1771867.html.
In other news, Director John D. Bowlin purchased 40,000 shares of the business’s stock in a transaction that occurred on Friday, August 25th. The shares were bought at an average cost of $5.50 per share, for a total transaction of $220,000.00. Following the acquisition, the director now owns 56,028 shares of the company’s stock, valued at approximately $308,154. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.07% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA grew its stake in Vitamin Shoppe by 2.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock worth $108,000 after acquiring an additional 192 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in Vitamin Shoppe by 18.1% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,410 shares of the specialty retailer’s stock worth $110,000 after acquiring an additional 1,440 shares in the last quarter. Wolverine Trading LLC bought a new position in Vitamin Shoppe in the 2nd quarter worth about $131,000. UBS Asset Management Americas Inc. grew its stake in Vitamin Shoppe by 17,041.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,999 shares of the specialty retailer’s stock worth $140,000 after acquiring an additional 11,929 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in Vitamin Shoppe by 0.8% in the 2nd quarter. Arizona State Retirement System now owns 12,460 shares of the specialty retailer’s stock worth $145,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 98.39% of the company’s stock.
Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with our FREE daily email newsletter.